Clinical Research Directory
Browse clinical research sites, groups, and studies.
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
Sponsor: Chinese University of Hong Kong
Summary
Cerebral small vessel disease (cSVD), a result of neurovascular cell dysfunction, is a major cause of stroke, dementia and mobility problems worldwide. Vascular risk factor control alone may not be sufficient to prevent the development of vascular cognitive impairment (VCI) in patients with cSVD according to previous clinical trials. The presence of glucagon-like peptide-1 receptor (GLP-1R) in cerebral microglia may reveal a potential therapeutic target for prevention of cSVD progression and its disabling clinical outcomes. At the cellular and animal experimentation levels, GLP-1R agonist demonstrated reversal of some pathogenic processes in cSVD. However, its application to cSVD patients remains to be elucidated. Investigator aims to investigate the safety and efficacy of GLP-1R agonist in patients with moderate-to-severe cSVD.
Official title: GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) - A Pilot Study
Key Details
Gender
All
Age Range
55 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
110
Start Date
2022-05-25
Completion Date
2026-12
Last Updated
2026-02-24
Healthy Volunteers
No
Conditions
Interventions
Exenatide extended release
2mg once weekly via subcutaneous injection
Locations (1)
Chinese University of Hong Kong
Hong Kong, Hong Kong